Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528398 · ClinicalTrials.gov registry record · Phase 2
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT00528398: Completed Phase 2 study, sponsored by City of Hope Medical Center.
NCT00528398 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 111 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00528398, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving idarubicin together with high-dose cytarabine works in treating patients with acute myeloid leukemia.
Primary Outcome
The peripheral blood neutrophil count is \>= 1.5 x 10\^9 / L and platelets more than 100 x 10\^9 / L. Leukemia blast cells are not present in the peripheral blood. The cellularity of the bone marrow is more than 20% with maturation of all cell lines. The bone marrow contains less than 5% blast cells, and Auer rods is not detectable.
Interventions
- DRUG cytarabine
- DRUG idarubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 1994-09 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
What the finished NCT00528398 record still lists
NCT00528398 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 2 interventions - of which cytarabine is the first listed.
NCT00528398 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00528398 about?
NCT00528398 is a clinical study titled "Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II...
What is the current status of trial NCT00528398?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 1994-09. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00528398?
The interventions under investigation include: cytarabine (DRUG), idarubicin (DRUG).
Who is sponsoring clinical trial NCT00528398?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00528398's enrollment target sits among peer trials
111 632nd of 2000 higher than 1,369 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia